Prices delayed by at least 15 minutes | Print
MEI Pharma (MEIP)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Address
3611 Valley Centre Drive
Suite 500
San Diego
CA
USA
92130
Telephone
+1 858 3697199
Forecast key dates
Name | Key Date |
---|---|
MEI Pharma Inc Second Quarter Earnings Results for 2025 | 2025-02-13T00:00:00 |
MEI Pharma Inc Annual General Meeting for 2024 | 2024-12-18T09:00:00 |
MEI Pharma Inc First Quarter Earnings Results for 2025 | 2024-11-08T00:00:00 |
MEI Pharma Inc Fourth Quarter Earnings Conference Call for 2024 | 2024-09-26T17:00:00 |
MEI Pharma Inc Fourth Quarter Earnings Results for 2024 | 2024-09-26T00:00:00 |
MEI Pharma Inc Annual Report for 2024 | 2024-09-26T00:00:00 |
MEI Pharma Inc Third Quarter Earnings Results for 2024 | 2024-05-10T00:00:00 |
Previous key dates
Name | Key Date |
---|---|
MEI Pharma Inc Third Quarter Earnings Results for 2024 | 2024-05-10T00:00:00 |
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum | 2024-04-16T13:30:00 |
MEI Pharma Inc Second Quarter Earnings Results for 2024 | 2024-02-13T00:00:00 |
MEI Pharma Inc Annual General Meeting for 2023 | 2023-12-18T09:00:00 |
MEI Pharma Inc First Quarter Earnings Results for 2024 | 2023-11-09T00:00:00 |
MEI Pharma Inc Fourth Quarter Earnings Conference Call for 2023 | 2023-09-26T17:00:00 |
MEI Pharma Inc Annual Report for 2023 | 2023-09-26T00:00:00 |
MEI Pharma Inc Fourth Quarter Earnings Result for 2023 | 2023-09-26T00:00:00 |
MEI Pharma Inc Third Quarter Earnings Results for 2023 | 2023-05-11T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.